Table 2 lists other genes nonrelated to dopamine that were investigated in PD pharmacogenetic studies, as with dopaminergic genes the main outcome investigated was levodopa adverse effects.
NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...